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A B S T R A C T
Purpose
The extent of lymph node dissection appropriate for gastric cancer is still under debate. We have
conducted a randomized trial to compare the results of a limited (D1) and extended (D2) lymph node
dissection in terms of morbidity, mortality, long-term survival and cumulative risk of relapse. We have
reviewed the results of our trial after follow-up of more than 10 years.
Patients and Methods
Between August 1989 and June 1993, 1,078 patients with gastric adenocarcinoma were randomly
assigned to undergo a D1 or D2 lymph node dissection. Data were collected prospectively, and patients
were followed for more than 10 years.
Results
A total of 711 patients (380 in the D1 group and 331 in the D2 group) were treated with curative intent.
Morbidity (25% v 43%; P  .001) and mortality (4% v 10%; P  .004) were significantly higher in the
D2 dissection group. After 11 years there is no overall difference in survival (30% v 35%; P  .53). Of
all subgroups analyzed, only patients with N2 disease may benefit of a D2 dissection. The relative risk
ratio for morbidity and mortality is significantly higher than one for D2 dissections, splenectomy,
pancreatectomy, and age older than 70 years.
Conclusion
Overall, extended lymph node dissection as defined in this study generated no long-term survival
benefit. The associated higher postoperative mortality offsets its long-term effect in survival. For
patients with N2 disease an extended lymph node dissection may offer cure, but it remains difficult to
identify patients who have N2 disease. Morbidity and mortality are greatly influenced by the extent of
lymph node dissection, pancreatectomy, splenectomy and age. Extended lymph node dissections may
be of benefit if morbidity and mortality can be avoided.
J Clin Oncol 22:2069-2077. © 2004 by American Society of Clinical Oncology
INTRODUCTION
Gastric cancer is a common malignancy world-
wide. Even in a low-incidence country like the
Netherlands, it is ranked fifth with respect to in-
cidence. Despite declining incidence, mortality
ofgastriccancerremainshigh.Surgeryistheonly
possible curative treatment, and results of gas-
trectomy have improved throughout the years
with respect to survival, morbidity, and postop-
erative mortality.1,2
It is not clear, however, if extended
lymph node dissection contributes to this
improvement. Despite promising results in
nonrandomized studies, improved survival
has never been demonstrated in random-
ized trials.3-6 In all these randomized trials,
postoperative morbidity and mortality were
significantly higher in the extended (D2)
dissection group. Within the Dutch Gastric
Cancer Trial (DGCT), the number of early
gastric cancers was surprisingly high, and it
has been argued that any beneficial effect of
extended lymph node dissection, which
would be expected in more advanced dis-
ease, might have been attenuated. We have
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Fig 1. Lymph node stations surround-
ing the stomach. 1, right cardial nodes;
2, left cardial nodes; 3, nodes along the
lesser curvature; 4, nodes along the
greater curvature; 5, suprapyloric
nodes; 6, infrapyloric nodes; 7, nodes
along the left gastric artery; 8, nodes
along the common hepatic artery; 9,
nodes around the celiac axis; 10,
nodes at the splenic hilus; 11, nodes
along the splenic artery; 12, nodes in
the hepatoduodenale ligament; 13,
nodes at the posterior aspect of the
pancreas head; 14, nodes at the root of
the mesenterium; 15, nodes in the
mesocolon of the transverse colon; 16,
para-aortic nodes.
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therefore reviewed the results of our randomized limited
lymph node dissection (D1) versus extended lymph node
dissection (D2) trial after follow-up of more than 10 years
and focused on subgroups and prognostic factors.
PATIENTS AND METHODS
Patients with gastric adenocarcinoma were enrolled in the DGCT
between August 1989 and July 1993. Eligible patients were ran-
domly assigned for D1 (conventional) or D2 (extended) lymph
node dissection if at laparotomy, no signs of distant lymph node,
hepatic or peritoneal metastases were found. In case of metastases,
palliative surgery without formal lymph node dissection was done.
The trial protocol has previously been published.7
D1 and D2 dissection were defined according to the guide-
lines of the Japanese Research Society for the Study of Gastric
Cancer.8 These guidelines are also recommended by the American
Joint Committee on Cancer, in its fourth Manual for Staging of
Cancer, and by the International Union Against Cancer.9,10 In
these guidelines, 16 different lymph node compartments (sta-
tions) are identified surrounding the stomach (Fig 1). In general,
the perigastric lymph node stations along the lesser (stations 1, 3,
and 5) and greater (stations 2, 4, and 6) curvature are grouped N1,
whereas the nodes along the left gastric (station 7), common
Table 1. Characteristics of 711 Patients and Tumors After Resection With Curative Intent and Status at Last Follow-Up
Characteristic
Dissection Group
D1 (n  380) D2 (n  331)
No. of Patients % No. of Patients %
Median age, years 67 65
Sex
Male 215 187
Female 165 144
Median No. of lymph nodes investigated 17 30
Status after resection
Location of tumor
More than two thirds of stomach 25 7 24 7
Upper third (C) 39 10 34 10
Middle third (M) 108 28 92 28
Distal third (A) 207 54 180 54
Unknown 1  1 1  1
Pathologic stage of disease
T0 2  1 3  1
T1 98 26 85 26
T2 181 48 152 46
T3 94 25 82 25
T4 3  1 9 2
Tx 2  1 0 0
Lymph node involvement 205 54 185 56
R0 resection 339 89 293 89
Type of gastrectomy
Total 115 30 128 38
Partial 265 70 205 62
Resection of spleen 41 11 124 37
Resection of tail of pancreas 10 3 98 30
Status at last follow-up
Alive
Without recurrence 112 98 116 99
With recurrence 2 2 1 1
Dead
Hospital death 15 4 32 10
Without recurrence† 82 31 86 40
With recurrence
Locoregional 56 21 40 19
Locoregional and distant 98 37 55 26
Distant 30 11 33 15
NOTE. Some data have previously been reported.6
Abbreviations. D1, limited lymph node dissection group; D2, extended lymph node dissection group.
Because of rounding, percentages may not total 100.
†These numbers include hospital deaths.
D2 Dissection Beneficial for Some Patients
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hepatic (station 8), celiac (station 9), and splenic (stations 10 and
11) arteries are grouped N2.
D1 dissection entails removal of the involved part of the
stomach (distal or total), including greater and lesser omentum.
The spleen and pancreas tail are only resected when necessitated
by tumor invasion. For a D2 dissection, the omental bursa is
removed with the front leave of the transverse mesocolon, and the
mentioned vascular pedicles of the stomach are cleared com-
pletely. Standard resection of the spleen and pancreatic tail was
only done in proximal tumors to achieve adequate removal of D2
lymph node stations 10 and 11.
Patients were randomly assigned before surgery to ensure
standardization of surgery. Patients randomly assigned to D1 dis-
section had their operation performed by their local surgeon,
supervised by the trial coordinator. For D2 dissections, one of nine
referent surgeons performed the operation at the local hospital.
These referent surgeons had been trained in D2 dissection by a
Japanese surgeon from the National Cancer Center Hospital in
Tokyo. Apart from standardizing surgery, they ensured that the
specimen was adequately divided into lymph node stations, which
were then further investigated by the local pathologist. Operations
were classified as R0 if there was microscopic complete tumor
removal, without N3 or N4 involvement and no malignant cells on
cytology of abdominal washing. For analysis of differences in
relapse rates, only patients were included who had had a R0
resection and who did not die because of complications. None of
the curative patients had adjuvant radiotherapy or chemotherapy.
In the hospital, death was defined as death within 30 days of
surgery or during hospital stay, if this was longer than 30 days. For
stage grouping, the new (2002) tumor-node-metastasis system
classification system was used.11 In this new classification lymph
nodes are no longer characterized by location but by the number
of metastatic regional lymph nodes. N1 stands for 1 to 6, N2 for 7
to 15, and N3 for more than 16 metastatic regional lymph nodes.
For statistical analysis the SPSS program (SPSS Inc, Chicago,
IL) was used. A P value of .05 was considered statistically signifi-
cant. Overall survival was calculated from the day of random
assignment until either day of death (event) or day of last
follow-up (censored). Relapse was also calculated from the day of
random assignment; the data of a patient were censored when at
last follow-up contact the patient was alive with no evidence of
disease. The 2 test was applied to evaluate differences in propor-
tions, and the Mann-Whitney test was used to assess the signifi-
cance of differences in hospital stay. The log-rank test was used to
evaluate difference between survival and relapse curves, although
the assumption of proportional hazards was not always satisfied.
The Cox proportional hazard model was used to test for interac-
tion between prognostic factors and lymph node dissection.
For the subgroup analysis, no adjustment for multiple testing
was applied. Interpretation of the results of subset analyses have to
be judged carefully and any significant results must be viewed as
hypotheses that require validation in subsequent studies. A P value
of .05 may not be strict enough for these subgroups.
RESULTS
Of 1,078 patients randomly assigned in the DGCT, 996 were
eligible. At the time of surgery, 285 patients (29%) had
peritoneal, hepatic or distant lymph node metastasis, or
locally irresectable tumor and they underwent noncurative
treatment deemed appropriate by their surgeon.
This analysis focuses on the 711 patients (71%) who
had a curative resection with D1 (n 380) or D2 (n 331)
lymph node dissection. The characteristics of the 711 cura-
tive patients are well balanced between the two treatment
groups, except for pancreatico-splenectomy, which was ex-
pected according to the protocol (Table 1).
Follow-up was continued until January 2003. Median
follow-up for all eligible patients is 11 years (range, 6.8 to 13.1
years). Four-hundred eighty patients (68%) are now deceased,
35% without and 65% with recurrent disease (Table 1). In the
hospital, death was 4% (n  15) for the D1 group and 10%
(n32) for the D2 group (P .004). At 11 years, survival rates
are 30% for D1 and 35% for D2 (P .53) The risk of relapse is
70% for D1 and 65% for D2 (P .43; Fig 2).
In a univariate analysis of all 711 patients, for none of the
subgroups based on the selected prognostic variables was a
significant impact found on survival rates between D1 and D2
dissection (Table 2). Analysis of interaction between covariates
and lymph node dissection shows no significance. The only
subgroup with a trend to benefit is the N2 disease group (Fig
3). Furthermore, there is no difference in survival after 11 years
Fig 2. Survival probability (A) and relapse risk (B) of all patients treated with
curative intent (n  711). D1, limited lymph node dissection group; D2,
extended lymph node dissection group.
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whether less than 15 lymph nodes, between 15 and 25 lymph
nodes, or more than 25 lymph nodes are harvested.
Lymph node stations 10 and 11 were resected in 112
and 124 patients, respectively. In the group of 18 patients
with metastasis in station number 10, survival after 11 years
is only 11%. In the group of 24 patients with lymph node
metastasis in station 11, survival after 11 years is only 8%. If
there are no metastases in lymph node stations 10 and 11,
the 11-year survival is 27% and 35%, respectively.
The relative risk ratio for morbidity and mortality is
significantly greater than one for D2 dissections, splenec-
tomy, pancreatectomy, and age older than 70 years (mor-
tality only; Table 3).
Patients older than 70 years have significantly higher mor-
bidity and hospital mortality and significantly shorter survival
compared with patients younger than 70 years. (Table 4).
DISCUSSION
For many years it has been debated whether an extended
lymph node dissection for gastric cancer is beneficial. The-
oretically, removal of a wider range of lymph nodes by
extended lymph node dissection increases the chances for
cure. Such resection, however, may be irrelevant if there are
no lymph nodes affected, if the cancer has developed into a
systemic disease, or if resection increases morbidity and
mortality substantially.
Long-term follow-up of the largest randomized study
of D1 and D2 dissection now clearly demonstrates that
overall, no improved survival or decreased relapse rates can
be obtained by D2 dissection. Extended lymph node dissec-
tion is even harmful in terms of increased morbidity and
hospital mortality, although many reports deny this. Specif-
ically, Japanese investigators have reported low operative
morbidity and mortality,12 but so far, studies have not been
randomized. A randomized Japanese study between D2 and
D4 dissections, that included 523 patients and closed in April
2001 found a hospital mortality of 0.8% in both groups. Ded-
icated centers in Western Europe have reported hospital mor-
tality rates of less then 5% for extended lymph node dissections
in selected patients.13-15 In our study, patients younger than 70
years had a hospital mortality rate of 5.9%.
Table 2. Univariate Analysis of Survival Rates 11 Years After Resection With Curative Intent (N  711)
Variable
Dissection Group
P
D1 D2
No. of Patients Survival % No. of Patients Survival %
Age, years
 70 252 37 229 41 .74
 70 128 19 102 24 .68
Pathologic stage
T1 98 57 85 55 .90
T2 181 28 152 35 .54
T3 94 8 82 17 .80
Lymph nodes
Negative 171 52 144 51 .93
Positive 209 13 187 23 .28
Lymph node stage
N0 171 52 144 51 .93
N1 138 20 113 30 .46
N2 50 0 47 21 .08
N3 21 0 27 0 .30
Tumor-node-metastasis stage‡
IA 75 60 69 58 .84
IB 97 47 72 44 .65
II 93 23 77 37 .10
IIIA 60 4 54 22 .38
IIIB 24 0 20 10 .55
IV 28 0 36 3 .19
Gastrectomy
Partial 265 35 205 43 .20
Total 115 20 126 24 .94
All patients 380 31 331 35 .53
Abbreviations: D1, limited lymph node dissection group; D2, extended lymph node dissection group; TNM, tumor-node-metastasis.
P values were derived by the log-rank test for the difference between the D1 and D2 groups.
†Stages T0 and T4 (five patients in the D1 group and 12 in the D2 group) have been omitted.
‡Stages according to the sixth edition of the TNM classification manual.11 TNM stage 0 (four patients in the D1 group and three in the D2 group) has been
omitted.
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Splenectomy and pancreatectomy are important risk
factors for morbidity and hospital mortality after D2 dissec-
tion,16,17 with a significant adverse effect on survival as
well.18 Two Japanese studies showed no beneficial effect on
survival if pancreatosplenectomy was combined with total
gastrectomy, whereas morbidity was increased in these pa-
tients.19,20 A randomized trial in Chile found no survival
benefit from a splenectomy in patients with total gastrec-
tomy, whereas morbidity was again significantly in-
creased.21 Another randomized trial to study the effect of
splenectomy is underway in Japan.22 In our study the risk
ratio for morbidity and mortality was significant for pan-
createctomy and splenectomy. The question is whether a
survival benefit can be achieved with an extended lymph
node dissection, if morbidity- and mortality-increasing
procedures such as pancreatectomy and splenectomy can
be avoided. A randomized English study supports this hy-
pothesis for patients with stage II and III disease.23 Pancreas
and spleen sparing procedures have now become standard
in Japan as well as many Western countries.
The main reason to do pancreatectomy and splenec-
tomy in D2 dissection was not to compromise an adequate
dissection of lymph node stations 10 and 11. Metastasis in
these lymph nodes, however, confers a poor prognosis. In
our study, patients with metastasis in these lymph nodes
have a survival rate at 11 years of 8% and 11%, respectively,
whereas patients without metastases have a survival rate of
27% and 35%, respectively. So the relevance of the dissec-
tion of these nodes has to be questioned as the survival
benefit is small and morbidity and hospital mortality are
significantly increased.
Total gastrectomy has a higher morbidity and hospital
mortality rate than partial gastrectomy. A randomized trial
in Italy showed that there is no survival benefit from a total
gastrectomy if resection margins are free of tumor.18 So
total gastrectomy should only be performed if the localiza-
tion of the tumor requires to do so.
With the aging of the populations of industrialized
countries, more elderly patients with gastric cancer will be
diagnosed. Population-based data from the Netherlands
show that from 1982 to 1992, 27% of newly diagnosed
patients were older than 80 years.24 In a study on gastric
cancer in the elderly by Klein Kranenbarg et al,25 it was
shown that there is no difference in resectability and cur-
ability rate between different age groups, but hospital mor-
tality increases with increasing age, especially older than 70
Fig 3. Survival of patients treated with curative intent according to N stage. (A), N0; (B), N1; (C), N2; (D), N3. D1, limited lymph node dissection group; D2, extended
lymph node dissection group.
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years. Differentiation between D1 and D2 dissections for
the age groups younger and older than 70 years shows that
the morbidity and hospital mortality is higher in the D2
dissection group compared with the D1 dissection group.
Although some authors do not regard age as an important
prognostic variable for survival, we believe that gastrecto-
mies should not be withheld from elderly patients but that
extended lymph node dissection should be avoided in
Western patients older than 70 years.
The new (2002) tumor-node-metastasis system classi-
fication system11 offers a better insight in subgroups with
different prognosis.26-28 Using this new classification sys-
tem, we studied the effect of D1 and D2 dissections in the
N0, N1, N2, and N3 groups and found what theoretically
might be expected—that the largest advantage is for the N2
disease group if they had a D2 dissection. This advantage
was less for the N0, N1, and N3 groups. So a D2 dissection
probably is the only possible cure for N2 patients. Given
that only 12% of all patients had N2 disease, it is not possible
to find this difference through the randomized groups. We
calculated that with exclusion of postoperative deaths, 21%
of the population ought to have N2 disease to make an
overall difference between D1 and D2 significant. Including
postoperative death, no such percentage will make the dif-
ference between the D1 and D2 significant.
At this moment N classification can only be concluded
postoperatively after histologic examination. Although we
have tested many possible prognostic factors and their com-
binations, such as T stage, tumor location in the stomach,
histologic characteristics (well v poorly differentiated,
WHO classification, Lauren classification, and Goseki clas-
sification), oncogene markers (p53, Rb, Myc, and Nm23),
adhesion molecules (Ep-CAM, E-Cadherin, CD44v5, and
CD44v6), and sucrose maltase expression, we have so far
not been able to identify any factor that can identify N2
patients preoperatively.29,30 We hope that promising results
from genomic profiling in the near future may help to
discriminate between patients with a high risk of lymph
node metastasis.31
The extent of surgery will especially be of influence on
locoregional control. Relapse after curative surgery because of
local recurrence or regional lymph node metastasis has been
shown in up to 87.5% of patients.32 In our trial, locoregional
recurrence was registered in 58% of the D1 group and in 45%
of the D2 group. In studies with extensive surgery (D2 or
more) local recurrence rates of less than 1% are reported.33
Another approach to improve locoregional control is postop-
Table 3. Relative Risk Ratio for Morbidity and Mortality After Resection With Curative Intent (n  711)
Factor
Total No. of
Patients
Morbidity Mortality
No. of Patients % RR 95% CI No. of Patients % RR 95% CI
Dissection
D1 380 94 25 15 4
D2 331 142 43 1.73 1.40 to 2.15 32 10 2.45 1.35 to 4.44
Splenectomy
D1 41
D2 124
No, both groups 546 59 11 26 5
Yes, both groups 165 54 33 3.03 2.19 to 4.19 21 13 2.67 1.55 to 4.62
Pancreatectomy
D1 10
D2 98
No, both groups 603 70 12 34 5
Yes, both groups 108 43 40 3.43 2.49 to 4.72 13 12 2.14 1.17 to 3.91
Age, years
 70 481 152 32 20 4
 70 230 80 37 1.10 0.88 to 1.37 27 12 2.82 1.62 to 4.93
Abbreviations: RR, relative risk; D1, limited lymph node dissection group; D2, extented lymph node dissection group.
Table 4. Impact of Age on Morbidity, Mortality, and Survival After
Resection With Curative Intent (N  711)
Age (years)
 70  70 P
Morbidity, %
D1 20.4 31.7 .01
D2 41.1 46.4 NS
Mortality, %
D1 1.7 7.6 .005
D2 5.9 17.0 .002
Mean survival, years
D1 6.27 4.43 .0001
D2 6.13 4.73 .009
Abbreviations: D1, limited lymph node dissection group; D2, extended
lymph node dissection group; NS, not significant.
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erative chemoradiotherapy, which has recently been suggested
as the standard of care treatment in the United States after a
curative resection of gastric adenocarcinoma.34 Because only
10% of these patients had the advised D2 lymph node dissec-
tion and 54% of the patients in that trial had a D0 lymph node
dissection, the question has raised whether the adjuvant treat-
ment given in that trial only compensates for inadequate sur-
gery. Five-year survival rates of the group that received adju-
vant chemoradiotherapy resemble those of the Dutch Gastric
Cancer Trial, where no adjuvant treatment was given. Al-
though the population of the INT 0116 trial34 had more ad-
vanced stages of disease compared with our trial, we believe
that this conclusion seems justified. Many comments on this
trial support our opinion.35-37 The effect of a limited lymph
node dissection on survival was also reported by the study
group itself.38 It is therefore doubtful if any survival advantage
of chemoradiotherapy would have been found if patients
would have had adequate surgery.
We conclude that there is no long-term overall survival
benefit from an extended lymph node dissection in Western
patients with gastric cancer. The associated higher postopera-
tive mortality offsets its long-term effect in survival. For pa-
tients with N2 disease, an extended lymph node dissection may
offer cure, but it remains difficult to identify patients who have
N2 disease. Morbidity and mortality are greatly influenced by
the extent of lymph node dissection, pancreatectomy, splenec-
tomy, and age. Extended lymph node dissections may be of
benefit if morbidity and mortality can be reduced.
  
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